In today’s competitive life sciences landscape, time is the ultimate currency. For a small biotech company developing a new C. difficile treatment, traditional study designs required over 1,000 patients an impossible scenario for limited budgets and urgent patient needs.

That’s where KerusCloud®, MMS’s proprietary simulation-guided study design platform, transformed the path forward. By creating virtual patient populations and running thousands of “what-if” simulations, MMS helped identify the optimal evidence package to support early regulatory approval.

This case study reveals how simulation-driven strategy and advanced analytics can help sponsors design smarter, faster trials while reducing costs and improving outcomes for patients worldwide.

Accelerate Regulatory Approval with KerusCloud® Simulation Design

Download your free Case Study today ↓

Key Benefits / What You’ll Learn:

• Cut years off development timelines through simulation-guided study optimization.
• Reduce clinical trial size by over 80% while maintaining statistical robustness.
• Lower development costs by $22.5M without compromising data quality.
• Engage regulators confidently with data-driven, evidence-backed scenarios.
• Empower early access and adaptive pathways with smarter, synthetic data modeling.

Developed and implemented by MMS statistical experts, KerusCloud® has helped sponsors achieve accelerated approvals through smarter, simulation-based evidence generation trusted by FDA and EMA reviewers.